Myovant Sciences Drug Patent Portfolio
Myovant Sciences owns 1 orange book drug protected by 7 US patents Given below is the list of Myovant Sciences's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11793812 | Methods of treating endometriosis | 03 May, 2038 | Active |
| US11033551 | Methods of treating uterine fibroids | 29 Sep, 2037 | Active |
| US11957684 | Treatment of heavy menstrual bleeding associated with uterine fibroids | 29 Sep, 2037 | Active |
| US11795178 | Compositions of thienopyrimidine derivatives | 27 Sep, 2033 | Active |
| US7300935 | Thienopyrimidine compounds and use thereof | 28 Jan, 2025 | Active |
| US8058280 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof | 28 Jan, 2025 | Active |
| US9346822 | Thienopyrimidine compounds and use thereof | 17 Feb, 2024 | Expired |
Latest Legal Activities on Myovant Sciences's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Myovant Sciences.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 17 Apr, 2024 | US11957684 |
| Mail Patent eGrant Notification | 16 Apr, 2024 | US11957684 |
| Patent eGrant Notification | 16 Apr, 2024 | US11957684 |
|
Recordation of Patent Grant Mailed
Critical
| 16 Apr, 2024 | US11957684 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 16 Apr, 2024 | US11957684 |
| Recordation of Patent eGrant | 16 Apr, 2024 | US11957684 |
|
Email Notification
Critical
| 28 Mar, 2024 | US11957684 |
|
Issue Notification Mailed
Critical
| 27 Mar, 2024 | US11957684 |
|
Email Notification
Critical
| 14 Mar, 2024 | US11957684 |
| Mailing Corrected Notice of Allowability | 14 Mar, 2024 | US11957684 |
| Dispatch to FDC | 13 Mar, 2024 | US11957684 |
| Workflow - Request for RCE - Finish | 13 Mar, 2024 | US11957684 |
|
Information Disclosure Statement considered
Critical
| 11 Mar, 2024 | US11957684 |
| Corrected Notice of Allowability | 11 Mar, 2024 | US11957684 |
|
Pubs Case Remand to TC
Critical
| 05 Mar, 2024 | US11957684 |
Myovant Sciences Drug Patents' Oppositions Filed in EPO
Myovant Sciences drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 15, 2022, by Sandoz Ag. This opposition was filed on patent number EP17823018A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17823018A | Dec, 2022 | SANDOZ AG | Granted and Under Opposition |
Myovant Sciences's Family Patents
Myovant Sciences Drug List
Given below is the complete list of Myovant Sciences's drugs and the patents protecting them.
1. Myfembree
Myfembree is protected by 7 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11793812 | Methods of treating endometriosis |
03 May, 2038
(13 years from now)
| Active |
| US11033551 | Methods of treating uterine fibroids |
29 Sep, 2037
(12 years from now)
| Active |
| US11957684 | Treatment of heavy menstrual bleeding associated with uterine fibroids |
29 Sep, 2037
(12 years from now)
| Active |
| US11795178 | Compositions of thienopyrimidine derivatives |
27 Sep, 2033
(8 years from now)
| Active |
| US7300935 | Thienopyrimidine compounds and use thereof |
28 Jan, 2025
(3 months from now)
| Active |
| US8058280 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
28 Jan, 2025
(3 months from now)
| Active |
| US9346822 | Thienopyrimidine compounds and use thereof |
17 Feb, 2024
(7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myfembree's drug page